Results 1 to 10 of about 9,651,090 (393)

2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Arthritis care & research, 2023
To provide evidence‐based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs).
A. Bass, E. Chakravarty, E. Akl, Clifton O. Bingham, L. Calabrese, L. Cappelli, S. Johnson, L. Imundo, K. Winthrop, R. Arasaratnam, Lindsey R. Baden, R. Berard, S. Bridges, Jonathan T. L. Cheah, J. R. Curtis, Polly J. Ferguson, I. Hakkarinen, K. Onel, Grayson Schultz, V. Sivaraman, Benjamin J. Smith, J. Sparks, Tiphanie P Vogel, E. Williams, C. Calabrese, Joanne S. Cunha, J. Fontanarosa, M. Gillispie‐Taylor, E. Gkrouzman, Priyanka Iyer, K. Lakin, A. Legge, Mindy S. Lo, M. M. Lockwood, R. Sadun, Namrata Singh, Nancy M. Sullivan, H. Tam, Marat Turgunbaev, Amy S. Turner, J. Reston   +40 more
semanticscholar   +1 more source

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Annals of the Rheumatic Diseases, 2021
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
V. Furer, T. Eviatar, D. Zisman, H. Peleg, D. Paran, D. Levartovsky, M. Zisapel, O. Elalouf, I. Kaufman, R. Meidan, A. Broyde, A. Polachek, J. Wollman, I. Litinsky, K. Meridor, H. Nochomovitz, Adi Silberman, D. Rosenberg, J. Feld, A. Haddad, Tal Gazzit, M. Elias, N. Higazi, F. Kharouf, G. Shefer, O. Sharon, S. Pel, S. Nevo, O. Elkayam   +28 more
semanticscholar   +1 more source

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Annals of the Rheumatic Diseases, 2021
Objectives To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020).
Anja Strangfeld, M. Schäfer, M. Gianfrancesco, S. Lawson-Tovey, J. Liew, L. Ljung, E. Mateus, C. Richez, M. Santos, G. Schmajuk, C. Scirè, E. Sirotich, J. Sparks, P. Sufka, T. Thomas, L. Trupin, Z. Wallace, Sarah Al-Adely, J. Bachiller-Corral, S. Bhana, P. Cacoub, L. Carmona, R. Costello, W. Costello, L. Gossec, R. Grainger, E. Hachulla, R. Hasseli, J. Hausmann, K. Hyrich, Z. Izadi, L. Jacobsohn, P. Katz, L. Kearsley‐Fleet, P. Robinson, J. Yazdany, P. Machado   +36 more
semanticscholar   +1 more source

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

Nature Reviews Rheumatology, 2022
The COVID-19 pandemic has brought challenges for people with rheumatic disease in addition to those faced by the general population, including concerns about higher risks of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ...
R. Grainger, A. Kim, R. Conway, J. Yazdany, P. Robinson   +4 more
semanticscholar   +1 more source

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study

Human Vaccines & Immunotherapeutics, 2022
Patients with rheumatic diseases (RD) are considered to be a high-risk population for infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Huiqiong Zeng, Hanjiang Liu, Zhi Liu, Xiakai Zhou, Xiaoping Lu, Zhenbo Yan, Yan Zhou, Liping Dai, Yashuo Chen, Tingting Yang, Zhihua Yin, Zhizhong Ye   +11 more
doaj   +1 more source

Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview

Frontiers in Immunology, 2021
Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12).
C. Schinocca, C. Rizzo, S. Fasano, G. Grasso, L. La Barbera, F. Ciccia, G. Guggino   +6 more
semanticscholar   +1 more source

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

Annals of the Rheumatic Diseases, 2022
Objective To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE) and ...
G. Drosos, D. Vedder, E. Houben, L. Boekel, F. Atzeni, S. Badreh, D. Boumpas, N. Brodin, I. Bruce, M. González-Gay, S. Jacobsen, G. Kerekes, F. Marchiori, C. Mukhtyar, M. Ramos-Casals, N. Sattar, K. Schreiber, S. Sciascia, E. Svenungsson, Z. Szekanecz, A. Tausche, A. Tyndall, V. van Halm, A. Voskuyl, G. Macfarlane, M. Ward, M. Nurmohamed, Maria G. Tektonidou   +27 more
semanticscholar   +1 more source

LncRNA H19 induces immune dysregulation of BMMSCs, at least partly, by inhibiting IL-2 production

Molecular Medicine, 2021
Background Systemic lupus erythematosus (SLE) is a representative systemic autoimmune disease. LncRNA H19 has been identified to participate in various biological processes in human diseases. However, the role of H19 in SLE remains unclear.
Xinpeng Chen, Xiuxia Luo, Yazhi Wei, Hualin Sun, Liping Dai, Yidou Tangzhou, Huijie Jin, Zhihua Yin   +7 more
doaj   +1 more source

Glycobiology of rheumatic diseases

Nature Reviews Rheumatology, 2022
Autoantigen-specific IgG in patients with rheumatic diseases has a distinct N-glycosylation signature in the fragment crystallizable (Fc) domain, characterized by fucosylation without sialylation or galactosylation.
T. Kissel, R. Toes, T. Huizinga, M. Wuhrer   +3 more
semanticscholar   +1 more source

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Annals of the Rheumatic Diseases, 2021
Background The registration trials of messenger RNA (mRNA) vaccines against SARS-CoV-2 did not address patients with inflammatory rheumatic diseases (IRD).
Y. Braun-Moscovici, M. Kaplan, Maya Braun, D. Markovits, S. Giryes, K. Toledano, Y. Tavor, K. Dolnikov, A. Balbir-Gurman   +8 more
semanticscholar   +1 more source